포스포다이에스터레이스 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "포스포다이에스터레이스" in Korean language version.

refsWebsite

Global rank Korean rank

17nih.gov

4^th place

15doi.org

2^nd place

3^rd place

3semanticscholar.org

11^th place

310^th place

2worldcat.org

5^th place

11^th place

1web.archive.org

1^st place

1aspetjournals.org

6,663^rd place

2,136^th place

1archive.org

6^th place

18^th place

1phosphosite.org

low place

1aacrjournals.org

8,869^th place

4,351^st place

1harvard.edu

18^th place

27^th place

aacrjournals.org

cancerres.aacrjournals.org

Weiss,B. and Winchurch, R.A.: Analyses of cyclic nucleotide phosphodiesterases in lymphocytes from normal and aged leukemic mice. Cancer Res. 38:1274-1280, 1978 http://cancerres.aacrjournals.org/content/canres/38/5/1274.full.pdf

archive.org

Weiss B, Hait WN (1977). “Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents”. 《Annual Review of Pharmacology and Toxicology》 17: 441–77. doi:10.1146/annurev.pa.17.040177.002301. PMID 17360.

aspetjournals.org

molpharm.aspetjournals.org

Fertel R, Weiss B (July 1976). “Properties and drug responsiveness of cyclic nucleotide phosphodiesterases of rat lung”. 《Molecular Pharmacology》 12 (4): 678–87. PMID 183099. 2020년 4월 16일에 원본 문서에서 보존된 문서. 2021년 12월 2일에 확인함.

doi.org

dx.doi.org

Uzunov P, Weiss B (September 1972). “Separation of multiple molecular forms of cyclic adenosine-3',5'-monophosphate phosphodiesterase in rat cerebellum by polyacrylamide gel electrophoresis”. 《Biochimica et Biophysica Acta》 284 (1): 220–6. doi:10.1016/0005-2744(72)90060-5. PMID 4342220.
Strada SJ, Uzunov P, Weiss B (December 1974). “Ontogenetic development of a phosphodiesterase activator and the multiple forms of cyclic AMP phosphodiesterase of rat brain”. 《Journal of Neurochemistry》 23 (6): 1097–103. doi:10.1111/j.1471-4159.1974.tb12204.x. PMID 4375704. S2CID 46018589.
Weiss B, Hait WN (1977). “Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents”. 《Annual Review of Pharmacology and Toxicology》 17: 441–77. doi:10.1146/annurev.pa.17.040177.002301. PMID 17360.
Conti M (September 2000). “Phosphodiesterases and cyclic nucleotide signaling in endocrine cells”. 《Molecular Endocrinology》 14 (9): 1317–27. doi:10.1210/mend.14.9.0534. PMID 10976911.
Conti, M.; Beavo, J. (2007). “Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling”. 《Annual Review of Biochemistry》 76: 481–511. doi:10.1146/annurev.biochem.76.060305.150444. PMID 17376027.
Iffland A, Kohls D, Low S, Luan J, Zhang Y, Kothe M, Cao Q, Kamath AV, Ding YH, Ellenberger T (June 2005). “Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system”. 《Biochemistry》 44 (23): 8312–25. doi:10.1021/bi047313h. PMID 15938621.
Wood ER, Bledsoe R, Chai J, Daka P, Deng H, Ding Y, Harris-Gurley S, Kryn LH, Nartey E, Nichols J, Nolte RT, Prabhu N, Rise C, Sheahan T, Shotwell JB, Smith D, Tai V, Taylor JD, Tomberlin G, Wang L, Wisely B, You S, Xia B, Dickson H (August 2015). “The Role of Phosphodiesterase 12 (PDE12) as a Negative Regulator of the Innate Immune Response and the Discovery of Antiviral Inhibitors”. 《The Journal of Biological Chemistry》 290 (32): 19681–96. doi:10.1074/jbc.M115.653113. PMC 4528132. PMID 26055709.
Jeon YH, Heo YS, Kim CM, Hyun YL, Lee TG, Ro S, Cho JM (June 2005). “Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development”. 《Cellular and Molecular Life Sciences》 62 (11): 1198–220. doi:10.1007/s00018-005-4533-5. PMID 15798894. S2CID 9806864.
Khairallah M, Khairallah RJ, Young ME, Allen BG, Gillis MA, Danialou G, Deschepper CF, Petrof BJ, Des Rosiers C (May 2008). “Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency”. 《Proceedings of the National Academy of Sciences of the United States of America》 105 (19): 7028–33. Bibcode:2008PNAS..105.7028K. doi:10.1073/pnas.0710595105. PMC 2383977. PMID 18474859.
Wang C (January 2010). “Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia”. 《Current Opinion in Urology》 20 (1): 49–54. doi:10.1097/MOU.0b013e328333ac68. PMID 19887943. S2CID 205840859.
Orrú, Marco; Guitart, Xavier; Karcz-Kubicha, Marzena; Solinas, Marcello; Justinova, Zuzana; Barodia, Sandeep Kumar; Zanoveli, Janaina; Cortes, Antoni; Lluis, Carme; Casado, Vicent; Moeller, F. Gerard (April 2013). “Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans”. 《Neuropharmacology》 67C: 476–484. doi:10.1016/j.neuropharm.2012.11.029. ISSN 0028-3908. PMC 3562388. PMID 23261866.
da Silva, F H; Pereira, M N; Franco-Penteado, C F; De Nucci, G; Antunes, E; Claudino, M A (March 2013). “Phosphodiesterase-9 (PDE9) inhibition with BAY 73-6691 increases corpus cavernosum relaxations mediated by nitric oxide–cyclic GMP pathway in mice”. 《International Journal of Impotence Research》 25 (2): 69–73. doi:10.1038/ijir.2012.35. ISSN 0955-9930. PMID 23034509.
Hosseini-Zare MS, Salehi F, Seyedi SY, Azami K, Ghadiri T, Mobasseri M, Gholizadeh S, Beyer C, Sharifzadeh M (November 2011). “Effects of pentoxifylline and H-89 on epileptogenic activity of bucladesine in pentylenetetrazol-treated mice”. 《European Journal of Pharmacology》 670 (2–3): 464–70. doi:10.1016/j.ejphar.2011.09.026. PMID 21946102.
Gresele P, Momi S, Falcinelli E (October 2011). “Anti-platelet therapy: phosphodiesterase inhibitors”. 《British Journal of Clinical Pharmacology》 72 (4): 634–46. doi:10.1111/j.1365-2125.2011.04034.x. PMC 3195739. PMID 21649691.
Yuasa K, Mi-Ichi F, Kobayashi T, Yamanouchi M, Kotera J, Kita K, Omori K (November 2005). “PfPDE1, a novel cGMP-specific phosphodiesterase from the human malaria parasite Plasmodium falciparum”. 《The Biochemical Journal》 392 (Pt 1): 221–9. doi:10.1042/BJ20050425. PMC 1317681. PMID 16038615.

harvard.edu

adsabs.harvard.edu

Khairallah M, Khairallah RJ, Young ME, Allen BG, Gillis MA, Danialou G, Deschepper CF, Petrof BJ, Des Rosiers C (May 2008). “Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency”. 《Proceedings of the National Academy of Sciences of the United States of America》 105 (19): 7028–33. Bibcode:2008PNAS..105.7028K. doi:10.1073/pnas.0710595105. PMC 2383977. PMID 18474859.

nih.gov

ncbi.nlm.nih.gov

Uzunov P, Weiss B (September 1972). “Separation of multiple molecular forms of cyclic adenosine-3',5'-monophosphate phosphodiesterase in rat cerebellum by polyacrylamide gel electrophoresis”. 《Biochimica et Biophysica Acta》 284 (1): 220–6. doi:10.1016/0005-2744(72)90060-5. PMID 4342220.
Strada SJ, Uzunov P, Weiss B (December 1974). “Ontogenetic development of a phosphodiesterase activator and the multiple forms of cyclic AMP phosphodiesterase of rat brain”. 《Journal of Neurochemistry》 23 (6): 1097–103. doi:10.1111/j.1471-4159.1974.tb12204.x. PMID 4375704. S2CID 46018589.
Weiss B (1975). “Differential activation and inhibition of the multiple forms of cyclic nucleotide phosphodiesterase”. 《Advances in Cyclic Nucleotide Research》 5: 195–211. PMID 165666.
Fertel R, Weiss B (July 1976). “Properties and drug responsiveness of cyclic nucleotide phosphodiesterases of rat lung”. 《Molecular Pharmacology》 12 (4): 678–87. PMID 183099. 2020년 4월 16일에 원본 문서에서 보존된 문서. 2021년 12월 2일에 확인함.
Weiss B, Hait WN (1977). “Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents”. 《Annual Review of Pharmacology and Toxicology》 17: 441–77. doi:10.1146/annurev.pa.17.040177.002301. PMID 17360.
Conti M (September 2000). “Phosphodiesterases and cyclic nucleotide signaling in endocrine cells”. 《Molecular Endocrinology》 14 (9): 1317–27. doi:10.1210/mend.14.9.0534. PMID 10976911.
Conti, M.; Beavo, J. (2007). “Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling”. 《Annual Review of Biochemistry》 76: 481–511. doi:10.1146/annurev.biochem.76.060305.150444. PMID 17376027.
Iffland A, Kohls D, Low S, Luan J, Zhang Y, Kothe M, Cao Q, Kamath AV, Ding YH, Ellenberger T (June 2005). “Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system”. 《Biochemistry》 44 (23): 8312–25. doi:10.1021/bi047313h. PMID 15938621.
Wood ER, Bledsoe R, Chai J, Daka P, Deng H, Ding Y, Harris-Gurley S, Kryn LH, Nartey E, Nichols J, Nolte RT, Prabhu N, Rise C, Sheahan T, Shotwell JB, Smith D, Tai V, Taylor JD, Tomberlin G, Wang L, Wisely B, You S, Xia B, Dickson H (August 2015). “The Role of Phosphodiesterase 12 (PDE12) as a Negative Regulator of the Innate Immune Response and the Discovery of Antiviral Inhibitors”. 《The Journal of Biological Chemistry》 290 (32): 19681–96. doi:10.1074/jbc.M115.653113. PMC 4528132. PMID 26055709.
Jeon YH, Heo YS, Kim CM, Hyun YL, Lee TG, Ro S, Cho JM (June 2005). “Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development”. 《Cellular and Molecular Life Sciences》 62 (11): 1198–220. doi:10.1007/s00018-005-4533-5. PMID 15798894. S2CID 9806864.
Khairallah M, Khairallah RJ, Young ME, Allen BG, Gillis MA, Danialou G, Deschepper CF, Petrof BJ, Des Rosiers C (May 2008). “Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency”. 《Proceedings of the National Academy of Sciences of the United States of America》 105 (19): 7028–33. Bibcode:2008PNAS..105.7028K. doi:10.1073/pnas.0710595105. PMC 2383977. PMID 18474859.
Wang C (January 2010). “Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia”. 《Current Opinion in Urology》 20 (1): 49–54. doi:10.1097/MOU.0b013e328333ac68. PMID 19887943. S2CID 205840859.
Orrú, Marco; Guitart, Xavier; Karcz-Kubicha, Marzena; Solinas, Marcello; Justinova, Zuzana; Barodia, Sandeep Kumar; Zanoveli, Janaina; Cortes, Antoni; Lluis, Carme; Casado, Vicent; Moeller, F. Gerard (April 2013). “Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans”. 《Neuropharmacology》 67C: 476–484. doi:10.1016/j.neuropharm.2012.11.029. ISSN 0028-3908. PMC 3562388. PMID 23261866.
da Silva, F H; Pereira, M N; Franco-Penteado, C F; De Nucci, G; Antunes, E; Claudino, M A (March 2013). “Phosphodiesterase-9 (PDE9) inhibition with BAY 73-6691 increases corpus cavernosum relaxations mediated by nitric oxide–cyclic GMP pathway in mice”. 《International Journal of Impotence Research》 25 (2): 69–73. doi:10.1038/ijir.2012.35. ISSN 0955-9930. PMID 23034509.
Hosseini-Zare MS, Salehi F, Seyedi SY, Azami K, Ghadiri T, Mobasseri M, Gholizadeh S, Beyer C, Sharifzadeh M (November 2011). “Effects of pentoxifylline and H-89 on epileptogenic activity of bucladesine in pentylenetetrazol-treated mice”. 《European Journal of Pharmacology》 670 (2–3): 464–70. doi:10.1016/j.ejphar.2011.09.026. PMID 21946102.
Gresele P, Momi S, Falcinelli E (October 2011). “Anti-platelet therapy: phosphodiesterase inhibitors”. 《British Journal of Clinical Pharmacology》 72 (4): 634–46. doi:10.1111/j.1365-2125.2011.04034.x. PMC 3195739. PMID 21649691.
Yuasa K, Mi-Ichi F, Kobayashi T, Yamanouchi M, Kotera J, Kita K, Omori K (November 2005). “PfPDE1, a novel cGMP-specific phosphodiesterase from the human malaria parasite Plasmodium falciparum”. 《The Biochemical Journal》 392 (Pt 1): 221–9. doi:10.1042/BJ20050425. PMC 1317681. PMID 16038615.

phosphosite.org

[1] phosphosite.org

semanticscholar.org

api.semanticscholar.org

Strada SJ, Uzunov P, Weiss B (December 1974). “Ontogenetic development of a phosphodiesterase activator and the multiple forms of cyclic AMP phosphodiesterase of rat brain”. 《Journal of Neurochemistry》 23 (6): 1097–103. doi:10.1111/j.1471-4159.1974.tb12204.x. PMID 4375704. S2CID 46018589.
Jeon YH, Heo YS, Kim CM, Hyun YL, Lee TG, Ro S, Cho JM (June 2005). “Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development”. 《Cellular and Molecular Life Sciences》 62 (11): 1198–220. doi:10.1007/s00018-005-4533-5. PMID 15798894. S2CID 9806864.
Wang C (January 2010). “Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia”. 《Current Opinion in Urology》 20 (1): 49–54. doi:10.1097/MOU.0b013e328333ac68. PMID 19887943. S2CID 205840859.

web.archive.org

Fertel R, Weiss B (July 1976). “Properties and drug responsiveness of cyclic nucleotide phosphodiesterases of rat lung”. 《Molecular Pharmacology》 12 (4): 678–87. PMID 183099. 2020년 4월 16일에 원본 문서에서 보존된 문서. 2021년 12월 2일에 확인함.

worldcat.org

Orrú, Marco; Guitart, Xavier; Karcz-Kubicha, Marzena; Solinas, Marcello; Justinova, Zuzana; Barodia, Sandeep Kumar; Zanoveli, Janaina; Cortes, Antoni; Lluis, Carme; Casado, Vicent; Moeller, F. Gerard (April 2013). “Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans”. 《Neuropharmacology》 67C: 476–484. doi:10.1016/j.neuropharm.2012.11.029. ISSN 0028-3908. PMC 3562388. PMID 23261866.
da Silva, F H; Pereira, M N; Franco-Penteado, C F; De Nucci, G; Antunes, E; Claudino, M A (March 2013). “Phosphodiesterase-9 (PDE9) inhibition with BAY 73-6691 increases corpus cavernosum relaxations mediated by nitric oxide–cyclic GMP pathway in mice”. 《International Journal of Impotence Research》 25 (2): 69–73. doi:10.1038/ijir.2012.35. ISSN 0955-9930. PMID 23034509.